Dermatol Surg:这样治疗非黑素瘤皮肤癌是有效的

2016-08-04 Mechront 译 MedSci原创

根据最近的研究数据,使用激光烧蚀分数-局部氟尿嘧啶辅助治疗浅表基底细胞癌(BCC)和鳞状细胞原位癌(SCC)是有效的无创治疗手段。来自波士顿医疗中心皮肤科的Sarah H. Hsu博士和同事在以前的研究中发现了该治疗方式的短期疗效,但是长期结果仍未知。因此他们对30例原发性浅表型BCC或直径小于2cm的SCC患者使用了激光烧蚀分数和皮下外用5%的5-氟尿嘧啶7天。平均随访时间为15个月,26名患者

根据最近的研究数据,使用激光烧蚀分数-局部氟尿嘧啶辅助治疗浅表基底细胞癌(BCC)和鳞状细胞原位癌(SCC)是有效的无创治疗手段。

来自波士顿医疗中心皮肤科的Sarah H. Hsu博士和同事在以前的研究中发现了该治疗方式的短期疗效,但是长期结果仍未知。因此他们对30例原发性浅表型BCC或直径小于2cm的SCC患者使用了激光烧蚀分数和皮下外用5%的5-氟尿嘧啶7天。平均随访时间为15个月,26名患者中有20名在治疗4-8周时间里,进行了刮活组织检查,以验证组织间隙。

数据显示,总的治疗成功率为79%(95% CI,67-96)。SCC原位癌患者的成功率为92%,浅表BCC患者的成功率为67%。肿瘤位置或大小对治疗结果影响不显著。

研究人员写道,“大多数的治疗失败发生在治疗4-8周内,因此在一定程度上,可以通过治疗的初步反应预测长期的结果。随着人口老龄化,非黑素瘤皮肤癌的发生率增加,找到更加方便和符合成本效益的治疗方案是必要的,尤其是对复发低风险的浅表肿瘤。”

原始出处:

Ablative fractional laser with topical fluorouracil effective for some nonmelanoma skin cancers.Healio.August 3, 2016

Hsu S.H., et al. Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study..Dermatol Surg. 2016;doi:10.1097/DSS.0000000000000814.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034448, encodeId=9d7e2034448cd, content=<a href='/topic/show?id=d17499e79c8' target=_blank style='color:#2F92EE;'>#非黑素瘤皮肤癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99779, encryptionId=d17499e79c8, topicName=非黑素瘤皮肤癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Apr 02 15:47:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479409, encodeId=3ecf14e940963, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Aug 06 10:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96210, encodeId=41599621070, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96211, encodeId=3f4c96211c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034448, encodeId=9d7e2034448cd, content=<a href='/topic/show?id=d17499e79c8' target=_blank style='color:#2F92EE;'>#非黑素瘤皮肤癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99779, encryptionId=d17499e79c8, topicName=非黑素瘤皮肤癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Apr 02 15:47:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479409, encodeId=3ecf14e940963, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Aug 06 10:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96210, encodeId=41599621070, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96211, encodeId=3f4c96211c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034448, encodeId=9d7e2034448cd, content=<a href='/topic/show?id=d17499e79c8' target=_blank style='color:#2F92EE;'>#非黑素瘤皮肤癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99779, encryptionId=d17499e79c8, topicName=非黑素瘤皮肤癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Apr 02 15:47:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479409, encodeId=3ecf14e940963, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Aug 06 10:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96210, encodeId=41599621070, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96211, encodeId=3f4c96211c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=)]
    2016-08-05 doctorJiangchao

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2034448, encodeId=9d7e2034448cd, content=<a href='/topic/show?id=d17499e79c8' target=_blank style='color:#2F92EE;'>#非黑素瘤皮肤癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99779, encryptionId=d17499e79c8, topicName=非黑素瘤皮肤癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Apr 02 15:47:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479409, encodeId=3ecf14e940963, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sat Aug 06 10:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96210, encodeId=41599621070, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=96211, encodeId=3f4c96211c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Aug 05 21:58:00 CST 2016, time=2016-08-05, status=1, ipAttribution=)]
    2016-08-05 doctorJiangchao

    继续关注

    0

相关资讯

Ⅳ期结直肠癌原发肿瘤切除术或过度使用

美国M.D.安德森癌症研究中心的一项回顾性队列研究表明,尽管大多数Ⅳ期结直肠癌">结直肠癌患者均接受原发肿瘤切除术,但从2001年开始,原发肿瘤切除手术呈现逐渐递减趋势。虽然原发肿瘤切除比率下降了,但患者存活却较以往有所改善,提示原发肿瘤切除术对于患Ⅳ期结直肠癌患者的治疗可能不是常规必要的。论文1月14日在线发表于《美国医学会 外科学》(JAMA Surg)杂志。 该研究旨在评估原发肿瘤切

FDA批准Regorafenib治疗转移性结直肠癌

  Regorafenib是一种口服多激酶抑制剂,9月27日,美国食品与药物管理局(FDA)宣布,已批准将其用于治疗转移性结直肠癌。批准的适应证为治疗转移性结直肠癌患者,“这些患者之前已接受氟嘧啶、奥沙利铂和伊立替康为基础的化疗、1种抗VEGF治疗,此外,如为KRAS野生型,已接受1种抗EGFR治疗。”   经由FDA针对重大治疗进展或无充分治疗疾病的新药的审查程序,Regorafenib在生产

Lancet:转移胰腺导管腺癌患者,Nanoliposomal irinotecan联合氟尿嘧啶和叶酸一起服用效果如何?

通过对既往使用吉西他滨药物治疗的转移胰腺导管腺癌患者进行的Nanoliposomal irinotecan2期实验中,研究人员发现,患者的病情有所缓解。该实验的目的在于评估在3期临床试验中,Nanoliposomal irinotecan药物单独使用或结合氟尿嘧啶和叶酸的效果。

JCO:II至III期直肠癌患者的化疗新方案

  研究要点 本研究对有选择的放化疗,结合术前FOLFOX/贝伐单抗灌注方案进行了评价;32例研究参试者均取得R0切除结局;该结果表明,对于经筛选后的临床II期至III期直肠癌患者,新辅助化疗及选择性放疗似乎并不会损害患者结局。 参试患者无病生存与总生存结局   尽管临床II至III期直肠癌患者通过新辅助放化疗手段可取得较低的局部复发率,但却会

Lancet:氟尿嘧啶与提高乳腺癌无病存活率无关

氨茴环霉素和紫杉烷相结合的化疗方案可以改善早期乳腺癌的结果。最广泛地与紫杉烷相结合的药物有阿霉素和环磷酰胺(AC),或者表阿霉素和环磷酰胺(EC),或者氟尿嘧啶、阿霉素和环磷酰胺(FAC),或者氟尿嘧啶、表阿霉素和环磷酰胺(FEC)。氟尿嘧啶对AC或者EC治疗处方的贡献尚不明确。多个随机试验曾尝试评估剂量密度化疗在早期乳腺癌治疗中的作用。但鲜有试验是进行了合适的研究设计。因此,剂量密度辅助化疗

JNCI:缺陷错配修复结肠癌III患者采用氟尿嘧啶联合奥沙利铂辅助化疗有效

有报告称缺陷错配修复(dMMR)结肠癌(CC)对于5-氟尿嘧啶(5FU)辅助化疗是有抗性的,然而初步数据表明患者对于奥沙利铂具有化疗敏感性。研究人员评估了氟尿嘧啶类药物对于dMMR CC患者使用和不使用奥沙利铂的情况下的疗效。这个多中心回顾性研究包括在2000和2011年之间所有接受根治性手术切除的II期或III dMMR CC患者。采用Cox模型分析预后因素,风险比(HRs)和95%可信区间(C